Abstract
This article summarizes epidemiological studies of inflammation markers, particularly C-reactive protein, and cardiovascular disease as of early 2002. Gaps in the research and the public health practice implications are also discussed. Although considerable work has been published since this review was completed, the perspectives and issues presented are still useful in evaluating the use of inflammation markers for risk stratisfication and prevention.
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Biomarkers / blood*
-
C-Reactive Protein / analysis
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / diagnosis*
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / prevention & control
-
Case-Control Studies
-
Confounding Factors, Epidemiologic
-
Cost-Benefit Analysis
-
Female
-
Humans
-
Inflammation / blood
-
Inflammation / complications
-
Inflammation / diagnosis*
-
Male
-
Mass Screening / economics
-
Mass Screening / standards
-
Predictive Value of Tests
-
Public Health Practice
-
Reference Values
-
Risk
-
Risk Assessment
Substances
-
Biomarkers
-
C-Reactive Protein